<?xml version="1.0" encoding="UTF-8"?>
<p>In the same context, MPOE-treated group 3 showed marked reductions in TGF-
 <italic>β</italic>1 and SMAD3 proteins expression (Figures 
 <xref ref-type="fig" rid="fig6">6(c)</xref> and 
 <xref ref-type="fig" rid="fig7">7(c)</xref>) compared to the CCl
 <sub>4</sub> fibrosis group (Figures 
 <xref ref-type="fig" rid="fig6">6(b)</xref> and 
 <xref ref-type="fig" rid="fig7">7(b)</xref>). According to Kanzler et al. [
 <xref rid="B47" ref-type="bibr">47</xref>] and Chen et al. [
 <xref rid="B71" ref-type="bibr">71</xref>], the observed suppression in TGF-
 <italic>β</italic>1 protein expression and the subsequent downregulation of SMAD3 in the livers of group 3 could explain the observed reduction of 
 <italic>α</italic>-SMA-positive cells (
 <xref ref-type="fig" rid="fig4">Figure 4(c)</xref>), collagen deposition (
 <xref ref-type="fig" rid="fig3">Figure 3(c)</xref>), and fibrosis % (
 <xref ref-type="fig" rid="fig3">Figure 3(e)</xref>) and the reduced fibrosis scores (
 <xref ref-type="table" rid="tab5">Table 5</xref>) in this group in comparison with the liver fibrosis control group. These findings support the antifibrogenic potential of MPOE against CCl
 <sub>4</sub>-induced liver fibrosis.
</p>
